Yesterday the Health, Education, Labor and Pensions (HELP) Committee approved legislation yesterday that will allow the Food and Drug Administration (FDA) to approve follow-on biologics in an expedited way, while preserving incentives to develop new therapies, without compromising patient safety.

The “Biologics Price Competition and Innovation Act of 2007

I would like to thank my colleagues for their hard work on this issue, particularly Sen. Orrin HatchOrrin Grant HatchTrump administration backs Oracle in Supreme Court battle against Google Timeline: Trump and Romney's rocky relationship Key Republicans say Biden can break Washington gridlock MORE (R-Utah), who has long been a leader in promoting affordable treatments and protecting patient safety. The bill our committee approved today builds on the legacy of the Hatch-Waxman generic drug bill, and I believe it strikes the right balance to be just as successful as that landmark legislation.

I introduced the “Biologics Price Competition and Innovation Act